Safety and Efficacy of BFH772 in Psoriasis Patients (NCT00987870) | Clinical Trial Compass
CompletedPhase 1/2
Safety and Efficacy of BFH772 in Psoriasis Patients
Germany15 participantsStarted 2009-09
Plain-language summary
This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Stable mild to moderate plaque psoriasis (BSA involvement \< 10% or PASI \< 10
* Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthritis
* Diagnosed or history of psoriasis for at least 6 months prior to screening
Exclusion Criteria:
* Nonplaque forms of psoriasis
* Drug-induced psoriasis
* Current use of beta blockers
* Congestive heart failure (NYHA \>III), QT interval \>450msec or poorly controlled diabetes mellitus
Other protocol-defined inclusion/exclusion criteria may apply